Key Aspects of Pharmaceutical Due Diligence Intellectual Property Assessment—Part I

Posted 01 October 2010 | By

Part one of this two part series provides a summary of the key aspects of US and EU patent exclusivity, as well as a discussion of patent exclusivity for the due diligence intellectual property assessment. Part II, to be published next month, will provide an overview of the due diligence process for the intellectual property assessment, highlighting the roles of the regulatory professional, patent attorney and CMC professional. It also will present a case study to tie together the concepts presented in both Parts I and II.


Regulatory Focus newsletters

All the biggest regulatory news and happenings.